Astoria Portfolio Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.76M Buy
10,976
+5,773
+111% +$1.24M 0.47% 35
2026
Q1
$1.03M Buy
5,203
+111
+2% +$24.6K 0.22% 71
2025
Q4
$1.17M Buy
5,092
+1,918
+60% +$437K 0.27% 59
2025
Q3
$734K Sell
3,174
-2,405
-43% -$490K 0.19% 89
2025
Q2
$1.06M Buy
5,579
+7
+0.1% +$1.3K 0.3% 68
2025
Q1
$987K Sell
5,572
-1,507
-21% -$293K 0.34% 74
2024
Q4
$1.24M Buy
7,079
+45
+0.6% +$8.27K 0.44% 45
2024
Q3
$1.37M Buy
7,034
+195
+3% +$36.4K 0.47% 37
2024
Q2
$1.17M Buy
6,839
+574
+9% +$95.1K 0.42% 39
2024
Q1
$1.01M Buy
6,265
+70
+1% +$12.1K 0.39% 48
2023
Q4
$1.07M Buy
6,195
+1,156
+23% +$169K 0.44% 40
2023
Q3
$732K Sell
5,039
-83
-2% -$12.2K 0.35% 53
2023
Q2
$684K Buy
5,122
+547
+12% +$80.2K 0.26% 69
2023
Q1
$731K Sell
4,575
-961
-17% -$147K 0.31% 59
2022
Q4
$828K Buy
5,536
+954
+21% +$146K 0.39% 48
2022
Q3
$615K Buy
4,582
+1,095
+31% +$157K 0.42% 58
2022
Q2
$534K Buy
3,487
+381
+12% +$58.2K 0.39% 62
2022
Q1
$503K Buy
3,106
+403
+15% +$58.5K 0.39% 60
2021
Q4
$366K Buy
+2,703
New +$319K 0.29% 92

Other funds holding ABBV

Astoria Portfolio Advisors's ABBV Position: Q2 2026 in Review

Astoria Portfolio Advisors increased its AbbVie (ABBV) stake by 111% in Q2 2026, buying an estimated $1.24M and bringing the position to 10,976 shares worth $2.76M. The position accounts for 0.47% of the portfolio, ranked #35.

Astoria Portfolio Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Astoria Portfolio Advisors held 10,976 shares of AbbVie worth $2.76M as of Q2 2026.
  • Astoria Portfolio Advisors bought 5,773 AbbVie shares in Q2 2026, an estimated $1.24M.
  • AbbVie made up 0.47% of Astoria Portfolio Advisors's portfolio in Q2 2026, its #35 holding.
  • Astoria Portfolio Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Astoria Portfolio Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.